更新于：2024-11-01

TUT7

更新于：2024-11-01

基本信息

别名

FLJ13409、HS2、KIAA1711

+ [8]

简介

Uridylyltransferase that mediates the terminal uridylation of mRNAs with short (less than 25 nucleotides) poly(A) tails, hence facilitating global mRNA decay (PubMed:19703396, PubMed:25480299). Essential for both oocyte maturation and fertility. Through 3' terminal uridylation of mRNA, sculpts, with TUT7, the maternal transcriptome by eliminating transcripts during oocyte growth (By similarity). Involved in microRNA (miRNA)-induced gene silencing through uridylation of deadenylated miRNA targets (PubMed:25480299). Also functions as an integral regulator of microRNA biogenesiS using 3 different uridylation mechanisms (PubMed:25979828). Acts as a suppressor of miRNA biogenesis by mediating the terminal uridylation of some miRNA precursors, including that of let-7 (pre-let-7). Uridylated pre-let-7 RNA is not processed by Dicer and undergo degradation. Pre-let-7 uridylation is strongly enhanced in the presence of LIN28A (PubMed:22898984). In the absence of LIN28A, TUT7 and TUT4 monouridylate group II pre-miRNAs, which includes most of pre-let7 members, that shapes an optimal 3' end overhang for efficient processing (PubMed:25979828, PubMed:28671666). Add oligo-U tails to truncated pre-miRNAS with a 5' overhang which may promote rapid degradation of non-functional pre-miRNA species (PubMed:25979828). Does not play a role in replication-dependent histone mRNA degradation (PubMed:18172165). Due to functional redundancy between TUT4 and TUT7, the identification of the specific role of each of these proteins is difficult (PubMed:25979828, PubMed:25480299, PubMed:19703396, PubMed:22898984, PubMed:18172165, PubMed:28671666). TUT4 and TUT7 restrict retrotransposition of long interspersed element-1 (LINE-1) in cooperation with MOV10 counteracting the RNA chaperonne activity of L1RE1. TUT7 uridylates LINE-1 mRNAs in the cytoplasm which inhibits initiation of reverse transcription once in the nucleus, whereas uridylation by TUT4 destabilizes mRNAs in cytoplasmic ribonucleoprotein granules (PubMed:30122351).

关联

项与 TUT7 相关的药物

TS-002266

靶点

Bcl-2 x TUT4 x TUT7

作用机制

Bcl-2抑制剂 [+2]

在研机构

Redona Therapeutics, Inc.初创企业

原研机构

Redona Therapeutics, Inc.初创企业

在研适应症

成人急性髓性白血病

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

TUT4/TUT7(Twentyeight-Seven)

靶点

TUT4 x TUT7

作用机制

TUT4 modulators [+1]

在研机构

Redona Therapeutics, Inc.初创企业

原研机构

Redona Therapeutics, Inc.初创企业

在研适应症

肿瘤

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

100 项与 TUT7 相关的临床结果

登录后查看更多信息

100 项与 TUT7 相关的转化医学

登录后查看更多信息

0 项与 TUT7 相关的专利（医药）

登录后查看更多信息

210

项与 TUT7 相关的文献（医药）

2024-12-01·International Immunopharmacology

Identification of RNA uridylation subtypes, and the prognostic and therapeutic value of RNA uridylation in systemic lupus erythematosus

Article

作者: Su, Sensen ; Ma, Zhanchuan ; Zhang, Yanli ; Yi, Huanfa ; Wu, Hao

The uridylation of 3'-RNA-a major process in epitranscriptomics- is catalyzed by terminal uridylyl transferases (TUTases), which are involved in multiple diseases and the immune response. Nonetheless, the role of TUTases in systemic lupus erythematosus (SLE) remains unknown. Here we identified increased level of MTPAP and ZCCHC6 and decreased level of PAPD5 and ZCCHC11 in SLE patients from Gene Expression Omnibus (GEO) GSE50772, GSE65391, and GSE121239. The random forest model was applied to screen 4 TUTase candidates (MTPAP, ZCCHC6, PAPD5, and ZCCHC11) to predict the susceptibility of SLE. A nomogram was constructed based on the 4 selected TUTase regulators. Decision curve analysis indicated that patients could benefit from the nomogram. Moreover, based on the 4 differentially expressed genes, individuals with SLE were divided into three patterns (Cluster A-C) using the consensus clustering method. Cluster B was enriched in adaptive immune cells, with the lowest TCE signature expression, manifesting a higher Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) than that in Cluster A and C. whereas, Cluster C was enriched in innate immune cells, with the highest T-cell exhaustion (TCE) signature expression, manifesting lower SLEDAI than that in Cluster B. Clinically, lupus nephritis (LN) patients manifested increased expression of MTPAP and ZCCHC6 and decreased expression of PAPD5 and ZCCHC11 in PBMCs using Quantitative Polymerase Chain Reaction (q-PCR). Immunohistochemistry (IHC) illustrated higher level of ZCCHC6 in the kidneys of LN patients than that in NC. In summary, TUTases could predict the occurrence of SLE and stratify patients based on their immune characteristics, eventually predicting the disease activity and guiding immune therapy.

2024-09-01·Nature Structural & Molecular Biology

Structural basis for activity switching in polymerases determining the fate of let-7 pre-miRNAs

Article

作者: Gilbert, Robert J C ; Zhang, Peijun ; Yi, Gangshun ; Brown, Tom ; Carrique, Loic ; El-Sagheer, Afaf ; Ye, Mingda ; Norbury, Chris J

AbstractTumor-suppressor let-7 pre-microRNAs (miRNAs) are regulated by terminal uridylyltransferases TUT7 and TUT4 that either promote let-7 maturation by adding a single uridine nucleotide to the pre-miRNA 3′ end or mark them for degradation by the addition of multiple uridines. Oligo-uridylation is increased in cells by enhanced TUT7/4 expression and especially by the RNA-binding pluripotency factor LIN28A. Using cryogenic electron microscopy, we captured high-resolution structures of active forms of TUT7 alone, of TUT7 plus pre-miRNA and of both TUT7 and TUT4 bound with pre-miRNA and LIN28A. Our structures reveal that pre-miRNAs engage the enzymes in fundamentally different ways depending on the presence of LIN28A, which clamps them onto the TUTs to enable processive 3′ oligo-uridylation. This study reveals the molecular basis for mono- versus oligo-uridylation by TUT7/4, as determined by the presence of LIN28A, and thus their mechanism of action in the regulation of cell fate and in cancer.

2024-06-01·New Phytologist

Positional cloning and characterization reveal the role of TaSRN‐3D and TaBSR1 in the regulation of seminal root number in wheat

Article

作者: Yao, Yingyin ; Xin, Mingming ; Li, Xuanshuang ; Guo, Weilong ; Ni, Zhongfu ; Chen, Zhaoyan ; Hu, Zhaorong ; Xing, Jiewen ; Liu, Jie ; Liu, Bin ; Peng, Huiru ; He, Fei ; Sun, Qixin ; Song, Long ; Xu, Weiya ; Cheng, Xuejiao ; Su, Zhenqi ; Chai, Lingling

Summary

Seminal roots play a critical role in water and nutrient absorption, particularly in the early developmental stages of wheat. However, the genes responsible for controlling SRN in wheat remain largely unknown.

Genetic mapping and functional analyses identified a candidate gene (TraesCS3D01G137200, TaSRN‐3D) encoding a Ser/Thr kinase glycogen synthase kinase 3 (STKc_GSK3) that regulated SRN in wheat. Additionally, experiments involving hormone treatment, nitrate absorption and protein interaction were conducted to explore the regulatory mechanism of TaSRN‐3D.

Results showed that the TaSRN‐3D4332 allele inhibited seminal roots initiation and development, while loss‐of‐function mutants showed significantly higher seminal root number (SRN). Exogenous application of epi‐brassinolide could increase the SRN in a HS2‐allelic background. Furthermore, chlorate sensitivity and 15N uptake assays revealed that a higher number of seminal roots promoted nitrate accumulation. TaBSR1 (BIN2‐related SRN Regulator 1, orthologous to OsGRF4/GL2 in rice) acts as an interactor of TaSRN‐3D and promotes TaBSR1 degradation to reduce SRN.

This study provides valuable insights into understanding the genetic basis and regulatory network of SRN in wheat, highlighting their roles as potential targets for root‐based improvement in wheat breeding.

项与 TUT7 相关的新闻（医药）

2024-03-04

·今日头条

《自然·医学》：菌株水平的肠菌特征，为跨癌症免疫治疗提供助力

03月04日的《热心肠日报》，我们解读了 15 篇文献，关注：癌症免疫治疗，具核梭杆菌，乳腺癌，大肠癌，罗斯氏菌，胰腺肿瘤，病理组学，ecDNA，胃癌，外泌体，微塑料，LISCure，Neurenati Therapeutics，Vivani Medical，BioMérieux，Lavie Bio。该篇日报由R·AI辅助创作生成，人工审核校对。 Nature子刊：肠道微生物如何影响免疫治疗效果？ Nature Medicine——[82.9] ① 本研究通过深入的宏基因组测序技术，发现了与癌症患者对免疫检查点阻断治疗（ICB）反应相关的肠道微生物特征，为未来的微生物组诊断或治疗提供了新的方向；② 研究表明，与微生物物种相比，菌株水平的微生物丰度，能更好地提高机器学习预测ICB反应和12个月无进展生存期的准确性；③ 通过对进一步六项类似研究的宏基因组分析，发现这些肠道微生物特征在不同癌症（跨癌种）和不同国家（跨国家）中具有普遍有效性，但前提是训练和测试队列使用一致的ICB方案；④ 研究强调了根据ICB治疗方案而非癌症类型，来定制肠道微生物组诊断或治疗的重要性。【原文信息】 A gut microbial signature for combination immune checkpoint blockade across cancer types 2024-03-01 , doi: 10.1038/s41591-024-02823-z 国内团队：具核梭杆菌仿生载体通过清除乳腺癌中的细菌增效化疗 Chem——[23.5] ① 苏州大学陈倩团队成功开发具核梭杆菌（Fn）仿生载体，通过清除乳腺癌中的细菌增加化疗疗效；② 瘤内Fn与乳腺癌中Gal-GalNAc的表达密切相关，并促进化疗耐药性；③ 将Fn细胞膜与抗生素装载脂质体融合成功制备纳米载体Colistin-LipoFM，可选择性地清除瘤内Fn，并显著提高化疗效果；④ 这种纳米载体还可干扰其他肿瘤内菌群，抑制乳腺癌肺转移，并进一步提升标准乳腺癌化疗疗效，且部分小鼠可实现肿瘤的完全消退；⑤ 因此，Fn仿生纳米载体作为一种优秀的针对细菌定植肿瘤的靶向药物传递载体，为癌症治疗提供了新思路。【原文信息】 Fusobacterium nucleatum-mimicking nanovehicles to overcome chemoresistance for breast cancer treatment by eliminating tumor-colonizing bacteria 2024-02-23 , doi: 10.1016/j.chempr.2024.01.030 秦环龙/蔚青/朱慧媛等Nature子刊：具核梭杆菌促进KRAS p.G12D突变大肠癌的机制 Nature Communications——[16.6] ① 同济大学秦环龙、蔚青、朱慧媛和团队揭示了具核梭杆菌Fn通过与RNA 解旋酶家族蛋白DHX15结合促进KRAS p.G12D 突变结直肠癌（CRC）的肿瘤进展机制；② Fn在KRAS p.G12D突变CRC肿瘤组织中富集，并促进Villin-Cre/KrasG12D+/-小鼠结直肠肿瘤发生；③ G12D小鼠模型和人类CRC组织中，狄氏副拟杆菌Pd与Fn竞争，口服Pd可减轻Fn依赖性CRC进展；④ 机制上，Fn侵入肠上皮细胞并与CRC肿瘤细胞中ERK/STAT3信号通路介导的的DHX15结合；⑤ Villin-Cre/KrasG12D+/-小鼠中，敲除Dhx15可减轻CRC表型；⑥ 本研究为个性化调节肠道菌群治疗CRC提供了新策略。【原文信息】 Fusobacterium nucleatum promotes tumor progression in KRAS p.G12D-mutant colorectal cancer by binding to DHX15 2024-02-24 , doi: 10.1038/s41467-024-45572-w 崔明/李源等Cell子刊：肠罗斯氏菌或可增敏大肠癌放疗 Cell Reports——[8.8] ① 中国医学科学院/北京协和医学院放射医学研究所崔明和李源团队揭示了肠道共生菌肠罗斯氏菌通过丁酸盐/OR51E1/RALB轴增强结直肠癌（CRC）对放射治疗的敏感性，为临床放疗提供了新的增敏策略；② 粪菌移植可导致肠罗斯氏菌在胃肠道中累积，提高CRC放疗疗效而不影响肿瘤发生；③ 原发性和CRC肝转移小鼠模型中，口服肠罗斯氏菌在CRC部位聚集并合成丁酸盐，使CRC对辐射敏感并减轻肠道毒性；④ 肠罗斯氏菌衍生的丁酸盐可激活CRC患者中过表达的G蛋白偶联受体OR51E1，并促进CRC细胞中的放射性自噬；⑤ 临床直肠癌组织和CRC小鼠模型中，OR51E1与RALB正相关，阻断OR51E1/RALB信号可抑制受辐射CRC细胞中丁酸盐引发的自噬。【原文信息】 Roseburia intestinalis sensitizes colorectal cancer to radiotherapy through the butyrate/OR51E1/RALB axis 2024-02-26 , doi: 10.1016/j.celrep.2024.113846 罕见胰腺肿瘤IPMN中不存在菌群 Gut——[24.5] ① 纳入190名胰管内乳头状黏液性肿瘤（IPMN）患者和19名阴性对照的338个胰腺囊肿液样本，对其进行16S rRNA测序，检测IPMN中是否存在可与下一代测序技术的多样性DNA背景区分开的菌群；② 与阴性对照组相比，胰腺囊肿液样本的菌群特征无差异，无法从分类多样性和微生物群落组成上区分；③ 在最近经历侵入性内窥镜的患者亚组中，出现与肠道相关微生物增加的异常信号，但这一信号并未表现出更高的分类多样性；④ 本研究表明胰腺囊性肿瘤为无菌环境，微生物模式与临床或囊肿参数之间无明显关联。【原文信息】 Absence of a pancreatic microbiome in intraductal papillary mucinous neoplasm 2024-03-01 , doi: 10.1136/gutjnl-2023-331012 国内团队JAMA子刊：病理组学或助力III期结肠癌患者的精准医疗 JAMA Surgery——[16.9] ① 南方医科大学严俊、中山大学王辉与团队发表文章，开发并验证了一种基于病理组学的特征，用于预测III期结肠癌患者的预后及化疗效益，为个性化治疗提供了新的依据；② 首先从南方医科大学南方医院的数字H-E染色图像中提取了总共114个病理组学特征，利用439名III期结肠癌患者组成的训练队列提取出4个特征，构建了一种病理组学的标志物；③ 多变量分析显示，病理组学标志物是与无病生存DFS（HR 2.46）和总生存OS（HR 2.78）相关的独立因素；④ 将病理组学标志物纳入诊断中，在训练和验证队列（n=346）中均表现出比传统模型更好的预测性能；⑤ 进一步分析显示，病理组学标志物得分低的患者更有可能从化疗中获益。【原文信息】 Pathomics Signature for Prognosis and Chemotherapy Benefits in Stage III Colon Cancer 2024-02-28 , doi: 10.1001/jamasurg.2023.8015 徐瑞华/王峰/赵齐等Nature子刊：适用于肿瘤外显子测序数据的ecDNA鉴定新方法 Nature Communications——[16.6] ① 中山大学肿瘤防治中心的徐瑞华、王峰、赵齐作为共同通讯在Nature Communications发表最新研究，开发出一种机器学习模型和工具GCAP，用于预测肿瘤基因组中的ecDNA扩增及其相关基因；② ecDNA扩增与微卫星不稳定性（MSI）间存在普遍的互斥模式；③ 在1015名CRC患者队列中，ecDNA扩增被确定为风险因素，并有助于细化基因组亚型；④ 四项临床试验数据表明，ecDNA扩增可作为胃肠癌免疫检查点阻断疗法的重要生物标志物，链接了ecDNA扩增与免疫治疗干预效果的临床证据。【原文信息】 Machine learning-based extrachromosomal DNA identification in large-scale cohorts reveals its clinical implications in cancer 2024-02-19 , doi: 10.1038/s41467-024-45479-6 Nature子刊：代谢组学机器学习模型可用于胃癌诊断和预后 Nature Communications——[16.6] ① 通过对702个血浆样本进行靶向代谢组分析，开发出基于机器学习的胃癌诊断和预后模型，为胃癌的早期检测和精准干预提供了新策略；② 构建出包含10种代谢物的胃癌诊断模型，在外部测试集中的敏感性达到0.905，显著优于传统的依赖癌症蛋白标志物的方法；③ 机器学习衍生的预后模型在预测胃癌患者风险分层方面，表现优于利用临床参数的传统模型；④ 本研究不仅揭示了胃癌的代谢重编程图谱，还识别出两套不同的生物标志物面板，分别用于早期检测和预后预测，助力胃癌的精准医疗。【原文信息】 Metabolomic machine learning predictor for diagnosis and prognosis of gastric cancer 2024-02-23 , doi: 10.1038/s41467-024-46043-y 南京医科大学：外泌体miR-1246调控肿瘤相关巨噬细胞极化 Advanced Science——[15.1] ① 南京医科大学的孙跃明和彭雯团队发表文章，揭示了外泌体miR-1246在肿瘤相关巨噬细胞(TAMs)极化中的关键作用；② 构建共培养系统，使得巨噬细胞的极化过程能够模拟肿瘤免疫微环境中TAMs的复杂性，发现外泌体miR-1246能够驱动TAMs的极化，干扰CD8+ T细胞的浸润和功能；③ 外泌体miR-1246的积累是来源于TUT7介导的小非编码RNA的降解，这一过程由SNRPB稳定，而不是来源于miR-1246的前体；④ 外泌体miR-1246含有Exo-基序，能与外泌体分选蛋白hnRNPA2B1结合，通过RNA测序分析发现，外源性miR-1246在转录后水平调控TAMs的极化，突出了NLRP3在巨噬细胞极化中的关键作用；⑤ 研究结果不仅强调了外泌体miR-1246在TAMs重编程中的触发作用，还揭示了其在肿瘤免疫微环境中丰度增加的机制。【原文信息】 The Uridylyl Transferase TUT7-Mediated Accumulation of Exosomal miR-1246 Reprograms TAMs to Support CRC Progression 2024-02-11 , doi: 10.1002/advs.202304222 新证据！微塑料或能促进肿瘤转移 Chemosphere——[8.8] ① 本研究揭示了微塑料在人类结直肠癌细胞中的积累及其对细胞迁移和分裂的影响，发现微塑料可能通过增强细胞迁移来促进肿瘤转移；② 0.25、1和10 μm的聚苯乙烯微纳塑料在四种人类结肠癌细胞系中都表现出显著的尺寸和浓度依赖性摄取，其中HCT116细胞摄取速率最高；③ 在细胞分裂过程中，微塑料被母细胞和子细胞共享，且无法被细胞排出；④ 短期暴露于0.25 μm的微塑料显著增加了细胞迁移能力，可能促进肿瘤转移；⑤ 塑料颗粒在单层和球形培养中都表现出高度的持久性，在多细胞球体的非增殖部分积累，且不干扰细胞的增殖或分裂。【原文信息】 Microplastics role in cell migration and distribution during cancer cell division 2024-02-27 , doi: 10.1016/j.chemosphere.2024.141463 LISCure活菌药LB-P8治疗PSC 2期临床获批 ① 2月29日，LISCure Biosciences公司宣布，旗下活菌药LB-P8治疗原发性硬化性胆管炎（PSC）的2期临床试验申请获得FDA批准；② LB-P8是一种单菌株活菌药产品，有效成分为嗜柠檬酸明串珠菌（ Leuconostoc citreum ）菌株，目前已获得FDA授予的治疗PSC孤儿药资格认定；③ PSC是一种罕见的、慢性胆汁淤积性肝病，目前没有获批药物，LB-P8有望成为新型治疗手段；④ 在1期临床研究中，LB-P8安全性和耐受性等数据得到确认，首例患者预计将于未来几个月内入组，2025年上半年将公布该研究的部分顶线结果。【原文信息】 LISCure Biosciences Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of LB-P8 for Primary Sclerosing Cholangitis (PSC) 2024-02-29 , PR Newswire 治疗罕见病公司「Neurenati Therapeutics」获得120万美元种子融资 ① 2月29日，Neurenati Therapeutics公司宣布，完成了由Genson Capital投资的120万美元（约合人民币864万元）种子轮融资；② 融资将用于加速Neurenati Therapeutics公司旗下治疗先天性巨结肠症管线药物NEU-001的临床开发；③ 先天性巨结肠症是一种罕见的胃肠道疾病，在加拿大每年约有100名新生儿罹患该病，目前该病治疗手段仅有手术，术后40%的患者会面临各种肠道炎症性疾病；④ Neurenati Therapeutics公司计划在2025年下半年提交NEU-001的新药临床试验申请。【原文信息】 Neurenati Therapeutics Concludes a 1.2 Million $ Seed Financing Round to Develop NEU-001 as a Promising Therapy for Hirschsprung Disease 2024-02-29 , Businesswire Vivani Medical公布两项减肥药物临床前研究数据 ① 2月28日，Vivani Medical公司公布了两项减肥药临床前研究数据，受此利好消息影响，其股价大涨270%；② NPM-115为艾塞那肽皮下植入剂，可实现每年给药2次，PM-139为司美格鲁肽皮下植入剂，可实现每年给药1次；③ 在高脂肪饮食诱导的肥胖小鼠模型上，持续治疗28天后，NPM-115组小鼠的体重相比安慰剂组降低了约20%，与阳性对照司美格鲁肽组相比减重效果相当；④ 在健康大鼠模型上，持续治疗15周后，NPM-139组大鼠的体重相比安慰剂组降低了约25%，预期效果持续时间为6个月。【原文信息】一年两次！艾塞那肽植入剂初显减重实力，GLP-1赛道竞争转向剂型战？ 2024-02-29 , 医药魔方 BioMérieux宣布与FDA达成战略研究合作 ① 2月28日，诊断产品制造商BioMérieux宣布与FDA达成战略研究合作；② 双方将共同开发抗食源性病原体的产品，以改善全球公共卫生；③ 此次战略合作将开展多个创新项目，旨在优化食品中潜在风险病原体的检测技术和微生物特征分析系统；④ 首批合作项目将基于BioMérieux的xPRO项目进行开展，使用新技术改进产志贺毒素大肠杆菌的分离、降低卡耶塔环孢子虫的检测限，并简化包括沙门氏菌和李斯特菌在内的食源性病原菌的特征分析方法。【原文信息】 bioMérieux and the Food and Drug Administration Launch Research Collaboration to Improve Microbial Detection Tools to Combat Food-Borne Pathogens 2024-02-28 , bioMérieux Lavie Bio获得250万美元里程碑付款 ① 2月28日，农业微生态公司Lavie Bio宣布，成功获得了Corteva公司支付的第二笔250万美元（约合人民币1799万元）预付款；② 2023年7月，双方签署一项合作协议，Corteva公司获得Lavie Bio公司生物一款杀菌剂产品的开发和商业化权利；③ 根据协议，Lavie Bio公司获得500万美元预付款，未来还将有资格获得生物杀菌剂产品销售里程碑付款和提成；④ Lavie Bio是Evogene公司的子公司，致力于通过微生物组技术开发生防菌和促生菌产品，来改善食品质量、可持续性和农业生产力等问题。【原文信息】 Lavie Bio Successfully Secures Second Half Advance Payment of $2.5M after Meeting Corteva's Licensing Agreement Requirements 2024-02-28 , PR Newswire 感谢本期日报的审核者：NL，圆圈儿，章台柳，九卿臣，RZN，Richard，lxx 点击阅读过去10天的日报： 0303 | 7天不吃饭，人体发生哪些变化？Nature子刊研究带来新知 0302 | 可吞咽设备：诊疗肠道疾病的新利器 0301 | 2月，最值得看的35篇肠道学术文献&产业要闻！ 0229 | 今日Nature：早期大肠癌如何躲过免疫系统？幕后黑手被锁定 0228 | 国内团队Nature子刊：抗性淀粉重塑菌群助减肥 0227 | 魏来/张峰/魏泓等Cell新发现：肠菌"不请自来"，推动遗传性致盲眼病 0226 | 用AI指导大肠癌治疗，大型临床研究再添新证 0225 | 65分综述详解：超加工食品和食品添加剂如何影响肠道健康？ 0224 | 陈思凡等Cell子刊新发现：促血栓的新型肠菌代谢物 0223 | 膳食纤维怎样影响代谢健康？18页综述一文讲透

微生物疗法临床研究免疫疗法